Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Sulfonamides/*pharmacokinetics"'
Publikováno v:
Toxicology letters, vol. 324, pp. 38-45
Tolylfluanid (TF) is a sensitizing biocide used in antifouling products and wood preservatives. Paint application is associated with skin exposure; however, the importance of this exposure route is uncertain as TF skin permeation rates are lacking in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::00c84efb7712e63abd8339ac59cec6b9
https://doi.org/10.1016/j.toxlet.2020.02.006
https://doi.org/10.1016/j.toxlet.2020.02.006
Autor:
Berger, Rolf M. F., Gehin, Martine, Beghetti, Maurice, Ivy, Dunbar, Kusic‐Pajic, Andjela, Cornelisse, Peter, Grill, Simon, Bonnet, Damien
Publikováno v:
British Journal of Clinical Pharmacology, 83(8), 1734-1744. Wiley
British Journal of Clinical Pharmacology, Vol. 83, No 8 (2017) pp. 1734-1744
British journal of clinical pharmacology, vol. 83, no. 8, pp. 1734-1744
British Journal of Clinical Pharmacology
British Journal of Clinical Pharmacology, Vol. 83, No 8 (2017) pp. 1734-1744
British journal of clinical pharmacology, vol. 83, no. 8, pp. 1734-1744
British Journal of Clinical Pharmacology
The aim of the present study was to investigate whether increasing the bosentan dosing frequency from 2 mg kg -1 twice daily (b.i.d.) to 2 mg kg -1 three times daily (t.i.d.) in children with pulmonary arterial hypertension (PAH) (from ≥3 months to
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::90514a22b48a6bcdd5ac2f77a188bbfc
https://research.rug.nl/en/publications/d33726ef-3dc0-40d5-93b1-d6dbb204e73c
https://research.rug.nl/en/publications/d33726ef-3dc0-40d5-93b1-d6dbb204e73c
Autor:
Jasper Dingemanse, Jochen Zisowsky, Martine Gehin, Andjela Kusic-Pajic, Maurice Beghetti, Andreas Krause
Publikováno v:
Paediatric Drugs, Vol. 19, No 2 (2017) pp. 121-130
Bosentan is approved for use in adult patients with pulmonary arterial hypertension. The primary aim of the pharmacokinetic modeling was the provision of a systematic guidance for study design and enhanced understanding of pharmacokinetics across the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2b23c39b870b0409c9b20e6d3d291a25
https://archive-ouverte.unige.ch/unige:107595
https://archive-ouverte.unige.ch/unige:107595
Autor:
Xavier Jaïs, Jasper Dingemanse, Andjela Kusic-Pajic, Adele Morganti, D. Dunbar Ivy, Damien Bonnet, Sheila G. Haworth, Ingram Schulze-Neick, Rudolphus Berger, Robyn J. Barst, Alain Fraisse, Nazzareno Galiè, Maurice Beghetti, Philippe Acar
Publikováno v:
British Journal of Clinical Pharmacology, Vol. 68, No 6 (2009) pp. 948-955
British Journal of Clinical Pharmacology
British Journal of Clinical Pharmacology, 68(6), 948-955. Wiley
British Journal of Clinical Pharmacology
British Journal of Clinical Pharmacology, 68(6), 948-955. Wiley
center dot Exposure to bosentan was lower in paediatric pulmonary arterial hypertension (PAH) patients treated with the marketed adult formulation at a dose of about 2 mg kg-1 when compared with adult PAH patients.center dot In healthy adult subjects
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f28746de409f1cb35e85ac12beefc9b1
https://doi.org/10.1111/j.1365-2125.2009.03532.x
https://doi.org/10.1111/j.1365-2125.2009.03532.x